Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)
Daisuke Sakai(Stowers Institute for Medical Research), Tatsuya Ioka(National Cancer Center Hospital East), Shogo Kobayashi(Osaka Gakuin University), Masashi Kanai(Kyoto University Hospital), Takuma Goto(Asahikawa Medical University), Masayuki Sho(Nara Medical University), Kenichi Yoshimura(Hiroshima University), Masanori Toyoda(Kobe University), Etsuro Hatano(Kyoto University), Yoshihumi Takeyama(Kindai University), Hiroki Yamaue(Wakayama Medical University), Hidetoshi Eguchi(Osaka Gakuin University), Satoru Seo(Kōchi University), Akinobu Taketomi(Hokkaido University), Junzo Shimizu(Osaka Rosai Hospital), Hideo Baba(Kaketsuken (Japan)), Tadatoshi Takayama(Nihon University), Chikashi Ishioka(Tohoku University), Hiroaki Nagano(Yamaguchi University), Jiro Fujimoto(Harvard University)
Cited by 109
Related Papers
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
|Journal of Hepatology|2003|1.6k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780